160 related articles for article (PubMed ID: 27667581)
1. Plant derived anti-cancerous secondary metabolites as multipronged inhibitor of COX, Topo, and aromatase: molecular modeling and dynamics simulation analyses.
Singh S; Awasthi M; Pandey VP; Dwivedi UN
J Biomol Struct Dyn; 2017 Nov; 35(14):3082-3097. PubMed ID: 27667581
[TBL] [Abstract][Full Text] [Related]
2. Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases.
Singh S; Pandey VP; Yadav K; Yadav A; Dwivedi UN
Curr Protein Pept Sci; 2020; 21(11):1103-1142. PubMed ID: 32951576
[TBL] [Abstract][Full Text] [Related]
3. DNA topoisomerase-directed anticancerous alkaloids: ADMET-based screening, molecular docking, and dynamics simulation.
Singh S; Das T; Awasthi M; Pandey VP; Pandey B; Dwivedi UN
Biotechnol Appl Biochem; 2016; 63(1):125-37. PubMed ID: 25594242
[TBL] [Abstract][Full Text] [Related]
4. Natural Products as Anticancerous Therapeutic Molecules with Special Reference to Enzymatic Targets Topoisomerase, COX, LOX and Aromatase.
Singh S; Awasthi M; Pandey VP; Dwivedi UN
Curr Protein Pept Sci; 2018; 19(3):238-274. PubMed ID: 28059043
[TBL] [Abstract][Full Text] [Related]
5. Lipoxygenase directed anti-inflammatory and anti-cancerous secondary metabolites: ADMET-based screening, molecular docking and dynamics simulation.
Singh S; Awasthi M; Pandey VP; Dwivedi UN
J Biomol Struct Dyn; 2017 Feb; 35(3):657-668. PubMed ID: 26942689
[TBL] [Abstract][Full Text] [Related]
6. Molecular docking and 3D-QSAR-based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer.
Awasthi M; Singh S; Pandey VP; Dwivedi UN
J Biomol Struct Dyn; 2015; 33(4):804-19. PubMed ID: 24702656
[TBL] [Abstract][Full Text] [Related]
7. Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of
Babu TM; Rammohan A; Baki VB; Devi S; Gunasekar D; Rajendra W
Drug Des Devel Ther; 2016; 10():3611-3632. PubMed ID: 27853354
[TBL] [Abstract][Full Text] [Related]
8. Molecular Docking of Bioactive Compounds Against BRCA and COX Proteins.
Prog Drug Res; 2016; 71():181-3. PubMed ID: 26939289
[TBL] [Abstract][Full Text] [Related]
9. Phytochemical Profiling, In Vitro and In Silico Anti-Microbial and Anti-Cancer Activity Evaluations and Staph GyraseB and
Mohammed HA; Khan RA; Abdel-Hafez AA; Abdel-Aziz M; Ahmed E; Enany S; Mahgoub S; Al-Rugaie O; Alsharidah M; Aly MSA; Mehany ABM; Hegazy MM
Molecules; 2021 Jan; 26(3):. PubMed ID: 33499325
[No Abstract] [Full Text] [Related]
10. Natural Product Inhibitors of Topoisomerases: Review and Docking Study.
Scotti L; Bezerra Mendonca FJ; Ribeiro FF; Tavares JF; da Silva MS; Barbosa Filho JM; Scotti MT
Curr Protein Pept Sci; 2018; 19(3):275-291. PubMed ID: 28079013
[TBL] [Abstract][Full Text] [Related]
11. Molecular docking studies of curcumin natural derivatives with DNA topoisomerase I and II-DNA complexes.
Kumar A; Bora U
Interdiscip Sci; 2014 Dec; 6(4):285-91. PubMed ID: 25118649
[TBL] [Abstract][Full Text] [Related]
12. Computational approaches elucidate the allosteric mechanism of human aromatase inhibition: a novel possible route to Small-molecule regulation of CYP450s activities?
Sgrignani J; Bon M; Colombo G; Magistrato A
J Chem Inf Model; 2014 Oct; 54(10):2856-68. PubMed ID: 25178092
[TBL] [Abstract][Full Text] [Related]
13. Repurposing of approved drugs for targeting CDK4/6 and aromatase protein using molecular docking and molecular dynamics studies.
Yousif FA; Alzain AA; Alraih AM; Ibraheem W
PLoS One; 2023; 18(9):e0291256. PubMed ID: 37682937
[TBL] [Abstract][Full Text] [Related]
14. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
López-Lázaro M; Willmore E; Jobson A; Gilroy KL; Curtis H; Padget K; Austin CA
J Nat Prod; 2007 Dec; 70(12):1884-8. PubMed ID: 18076140
[TBL] [Abstract][Full Text] [Related]
15. Molecular modeling of cationic porphyrin-anthraquinone hybrids as DNA topoisomerase IIβ inhibitors.
Arba M; Ruslin ; Ihsan S; Tri Wahyudi S; Tjahjono DH
Comput Biol Chem; 2017 Dec; 71():129-135. PubMed ID: 29153891
[TBL] [Abstract][Full Text] [Related]
16. Virtual Screening for Identification of Dual Inhibitors against CDK4/6 and Aromatase Enzyme.
Adon T; Shanmugarajan D; Ather H; Ansari SMA; Hani U; Madhunapantula SV; Honnavalli YK
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985460
[TBL] [Abstract][Full Text] [Related]
17. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells.
López-Lázaro M; Willmore E; Austin CA
Mutat Res; 2010 Feb; 696(1):41-7. PubMed ID: 20025993
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel aromatase inhibitors using a homogeneous time-resolved fluorescence assay.
Ji JZ; Lao KJ; Hu J; Pang T; Jiang ZZ; Yuan HL; Miao JS; Chen X; Ning SS; Xiang H; Guo YM; Yan M; Zhang LY
Acta Pharmacol Sin; 2014 Aug; 35(8):1082-92. PubMed ID: 25047514
[TBL] [Abstract][Full Text] [Related]
19. Sulfonanilide Derivatives in Identifying Novel Aromatase Inhibitors by Applying Docking, Virtual Screening, and MD Simulations Studies.
Rampogu S; Son M; Park C; Kim HH; Suh JK; Lee KW
Biomed Res Int; 2017; 2017():2105610. PubMed ID: 29312992
[TBL] [Abstract][Full Text] [Related]
20. Dual aromatase-steroid sulfatase inhibitors (DASI's) for the treatment of breast cancer: a structure guided ligand based designing approach.
Singh Y; Jaswal S; Singh S; Verma SK; Thareja S
J Biomol Struct Dyn; 2023 Dec; 41(20):10604-10626. PubMed ID: 36510679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
